As we have shown in our earlier study that the number of pre-antral and antral follicles which are present in polycystic ovaries is much larger than present in normal ovaries. Thus, it is evident that ovaries that are having polycystic ovaries have small follicles secreting more AMH than others. Whether antimullerian hormone (AMH) can help in predicting or diagnose in polycystic ovaries is being debated.
In our earlier studies we did show that using AMH does have a higher predictive value in the diagnosis of polycystic ovaries.
In a recent study done in Turkey, a similar combination was seen where antimullerian hormone and clinical features were combined. Thus, for a diagnosis of polycystic ovarian syndrome, the combination of period abnormalities (oligo-menorrhea) thus, for a diagnosis of polycystic ovaries, the combination of oligo-mennorrhea or signs of hypo-androgenism where an increased amount of androgens are present, there is almost an 83% sensitivity chance and a 100% specificity. This is very much similar to the studies which we did at the NHS Hospital in East London where we were combining it just with lutenising hormone, the AMH can be used in a very positive way of diagnosing polycystic ovaries.
Thus, the antimullerian hormone (AMH) is a useful diagnosis in those too old to diagnose polycystic ovarian syndrome and when combined with lutenising hormone, as well as along with signs of menstrual disorders and signs of increased androgens, can help in diagnosing polycystic ovarian syndrome.